益丰药房
(603939)
| 流通市值：285.47亿 | | | 总市值：285.53亿 |
| 流通股本：12.12亿 | | | 总股本：12.12亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 17,218,897,862.76 | 11,762,401,111.51 | 5,970,923,210.35 | 22,588,227,402.22 |
| 营业收入 | 17,218,897,862.76 | 11,762,401,111.51 | 5,970,923,210.35 | 22,588,227,402.22 |
| 二、营业总成本 | 15,712,009,022.92 | 10,676,892,508.96 | 5,394,533,467.59 | 20,616,597,464.58 |
| 营业成本 | 10,263,836,853.11 | 7,051,612,477.93 | 3,627,584,881.77 | 13,957,598,854.74 |
| 税金及附加 | 69,011,236.33 | 48,210,499.54 | 23,137,102.99 | 89,389,002.35 |
| 销售费用 | 4,475,400,595.82 | 3,005,586,267.14 | 1,456,924,559.93 | 5,487,450,160.02 |
| 管理费用 | 756,145,104.2 | 481,533,402.41 | 249,116,315.31 | 962,424,859.48 |
| 研发费用 | 25,185,648.1 | 16,865,821.99 | 9,772,260.99 | 33,549,984.91 |
| 财务费用 | 122,429,585.36 | 73,084,039.95 | 27,998,346.61 | 86,184,603.08 |
| 其中:利息费用 | 159,590,829.88 | 102,736,750.31 | 44,359,568.03 | 160,528,586.4 |
| 其中:利息收入 | 55,481,384.79 | 42,021,674.55 | 22,130,707.1 | 93,286,397.47 |
| 加:投资收益 | 76,803,405.41 | 49,447,044.49 | 14,930,288.87 | 42,372,208.53 |
| 资产处置收益 | 22,817,878.75 | 14,952,132.95 | 6,780,032.94 | 41,818,933.72 |
| 资产减值损失(新) | -59,754,324.5 | -38,797,603.61 | -19,301,520.8 | -72,633,545.68 |
| 信用减值损失(新) | -2,153,705.2 | -526,562.83 | 3,108,380.33 | -4,537,333.68 |
| 其他收益 | 40,942,345.23 | 23,383,714.37 | 11,615,548.55 | 76,134,913.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,585,544,439.53 | 1,133,967,327.92 | 593,522,472.65 | 2,054,785,114.19 |
| 加:营业外收入 | 8,127,203.89 | 5,411,664.44 | 2,453,100.38 | 12,704,923.41 |
| 减:营业外支出 | 13,679,482.67 | 7,882,548.33 | 2,737,276.93 | 29,896,117.67 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,579,992,160.75 | 1,131,496,444.03 | 593,238,296.1 | 2,037,593,919.93 |
| 减:所得税费用 | 381,573,694.73 | 271,425,909.71 | 147,286,412.75 | 456,662,974.49 |
| 六、净利润 | 1,198,418,466.02 | 860,070,534.32 | 445,951,883.35 | 1,580,930,945.44 |
| 持续经营净利润 | 1,198,418,466.02 | 860,070,534.32 | 445,951,883.35 | 1,580,930,945.44 |
| 归属于母公司股东的净利润 | 1,110,500,691.55 | 797,718,135.2 | 406,753,106.09 | 1,411,985,024.41 |
| 少数股东损益 | 87,917,774.47 | 62,352,399.13 | 39,198,777.26 | 168,945,921.03 |
| (一)基本每股收益 | 0.92 | 0.66 | 0.4 | 1.4 |
| (二)稀释每股收益 | 0.92 | 0.66 | 0.4 | 1.4 |
| 八、其他综合收益 | -89,370,675 | -119,801,550 | -44,204,850 | 38,418,418.54 |
| 归属于母公司股东的其他综合收益 | -89,370,675 | -119,801,550 | -44,204,850 | 38,418,418.54 |
| 九、综合收益总额 | 1,109,047,791.02 | 740,268,984.32 | 401,747,033.35 | 1,619,349,363.98 |
| 归属于母公司股东的综合收益总额 | 1,021,130,016.55 | 677,916,585.2 | 362,548,256.09 | 1,450,403,442.95 |
| 归属于少数股东的综合收益总额 | 87,917,774.47 | 62,352,399.13 | 39,198,777.26 | 168,945,921.03 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |